Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-60
SponsorGenieBiome Limited
About this trial
This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.
Eligibility criteria
Qualifiers
Females aged between 18 and 60 years who are newly diagnosed with stage I, II or III breast cancer
Planned chemotherapy including an anthracycline or taxane to be completed within 6 months
Mentally capable to participate in the study and provide informed consent
Disqualifiers
Pre-existing female-pattern baldness resembling picture I-3 or higher on the Savin scale at baseline
History of hair transplantation, psoriasis or severe scalp infection
Undergoing or plan to receive scalp cooling
Plan for immunotherapy
Trial design
Treatments tested in this trial
- BLHK03
- Active placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov